<p>Zimmer Biomet（紐約證券交易所代碼：ZBH - 獲取免費報告）在週五發佈的報告中，分析師 Stifel Nicolaus 將其目標價格從 115.00 美元上調至 118.00 美元，Benzinga 報道。該公司目前對這家醫療設備提供商的股票給予 “買入” 評級。Stifel Nicolaus 的目標價格意味着該公司股價有 17.47% 的潛在上漲空間。</p>
<ul>
<li>Intuitive Surgical 在機器人手術創新中領先</li>
</ul>
<p>其他一些研究分析師最近也對該公司發佈了報告。Raymond James Financial 將 Zimmer Biomet 的目標價格從 104.00 美元上調至 113.00 美元，並在 8 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。加拿大皇家銀行將 Zimmer Biomet 的目標價格從 112.00 美元上調至 115.00 美元，並在 8 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。Redburn Partners 在週四設定了 Zimmer Biomet 的目標價格為 130.00 美元。Rothschild Redb 在週四的研究報告中將 Zimmer Biomet 的評級提升至 “強力買入”。最後，Rothschild &amp; Co Redburn 在週四的研究報告中開始覆蓋 Zimmer Biomet，給予 “買入” 評級和 130.00 美元的目標價格。一位投資分析師對該股票給予 “強力買入” 評級，十位分析師給予 “買入” 評級，七位分析師給予 “持有” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 113.16 美元。</p>
<p>獲取 <strong>Zimmer Biomet</strong> 警報：</p>
<p><strong>閲讀我們關於 Zimmer Biomet 的最新研究報告</strong></p>
<h2>Zimmer Biomet 股價上漲 0.2%</h2>
<ul>
<li>2 家機器人手術公司挑戰 Intuitive Surgical 的領先地位</li>
</ul>
<p>週五午盤交易中，ZBH 股價上漲 0.24 美元，達到 100.45 美元。該公司交易了 288,498 股，較其平均交易量 1,964,456 股有所減少。該公司的市值為 199 億美元，市盈率為 24.44，市盈率/增長比率為 2.30，貝塔值為 0.68。Zimmer Biomet 的 1 年最低價為 89.22 美元，1 年最高價為 114.72 美元。該公司的 50 日移動平均價格為 99.93 美元，200 日移動平均價格為 99.46 美元。該公司的速動比率為 0.96，流動比率為 1.87，債務與股本比率為 0.54。</p>
<p>Zimmer Biomet（紐約證券交易所代碼：ZBH - 獲取免費報告）最後一次公佈財報是在 8 月 7 日，醫療設備提供商報告該季度每股收益為 2.07 美元，超出市場共識預期的 1.98 美元，超出 0.09 美元。該公司該季度的收入為 20.8 億美元，而市場共識預期為 20.6 億美元。Zimmer Biomet 的股本回報率為 12.76%，淨利潤率為 10.51%。該公司的季度收入較去年同期增長了 7.0%。在去年同期，該公司每股收益為 2.01 美元。Zimmer Biomet 已將其 2025 財年的指導目標設定為每股收益 8.100-8.300 美元。整體來看，股票分析師預測 Zimmer Biomet 在當前財年將發佈每股收益 8.22 美元。</p>
<h2>內部活動</h2>
<ul>
<li>波士頓科學：為什麼這家醫療科技巨頭不會放慢腳步</li>
</ul>
<p>在其他新聞中，SVP Lori Winkler 在 9 月 8 日的交易中出售了 1,500 股該公司的股票。股票以 104.15 美元的平均價格出售，總價值為 156,225.00 美元。交易完成後，這位高級副總裁直接持有該公司 6,833 股股票，價值 711,656.95 美元。這代表其持股比例減少了 18.00%。該交易已在與 SEC 的法律文件中披露，文件可通過此鏈接獲取。當前 1.39% 的股票由公司內部人士持有。</p>
<h2>對 Zimmer Biomet 的對沖基金看法</h2>
<p>幾家機構投資者最近修改了對 ZBH 的持股。Garde Capital Inc.在第一季度購買了價值約 29,000 美元的 Zimmer Biomet 新股份。Menard Financial Group LLC 在第四季度購買了價值約 30,000 美元的 Zimmer Biomet 新股份。Washington Trust Advisors Inc.在第一季度購買了價值約 30,000 美元的 Zimmer Biomet 新股份。Columbia River Financial Group LLC 在第一季度購買了價值約 30,000 美元的 Zimmer Biomet 新股份。最後，Cary Street Partners Investment Advisory LLC 在第二季度將其在 Zimmer Biomet 的股份提高了 83.7%。Cary Street Partners Investment Advisory LLC 現在擁有 327 股該醫療設備提供商的股票，價值 30,000 美元，此前在上個季度又購買了 149 股。88.89% 的股票由機構投資者持有。</p>
<h2>關於 Zimmer Biomet</h2>
<p>（獲取免費報告）</p>
<p>Zimmer Biomet Holdings, Inc 及其子公司在全球範圍內運營，作為一家醫療技術公司。該公司設計、製造和銷售骨科重建產品，如膝關節和髖關節產品；S.E.T.產品，包括運動醫學、生物製劑、足踝、四肢和創傷產品；顱面和胸部產品，包括面部和顱骨重建產品，以及固定和穩定胸部骨骼的產品，以促進心臟手術、創傷或胸部畸形後的癒合或重建。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Zimmer Biomet</li>
<li>異常交易量的股票：如何實時找到異常交易量股票</li>
<li>亞馬遜可能在十月達到歷史新高的三個原因</li>
<li>價值投資：在 2022 年這是一個好策略嗎？提示：永遠</li>
<li>Workday 上漲……達到新的歷史高股價</li>
<li>賣空 - 利弊分析</li>
<li>麥當勞：新的歷史高點是不可避免的</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Zimmer Biomet 嗎？</h2>
<p>在考慮 Zimmer Biomet 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Zimmer Biomet 並不在名單上。</p>
<p>雖然 Zimmer Biomet 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Stifel Nicolaus 將 Zimmer Biomet (NYSE:ZBH) 的目標價從 115.00 美元上調至 118.00 美元，維持 “買入” 評級。這個新目標暗示相較於前一交易日收盤價有 17.47% 的潛在上漲空間。其他分析師也提高了他們的目標價，平均目標為 113.16 美元。Zimmer Biomet 的股票目前交易價格為 100.45 美元，市值為 199 億美元。該公司報告的季度每股收益為 2.07 美元，超出預期，並已將 2025 財年的指引設定為每股收益 8.100-8.300</p>

<p>Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective boosted by analysts at Stifel Nicolaus from $115.00 to $118.00 in a report issued on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the medical equipment provider's stock. Stifel Nicolaus' price objective points to a potential upside of 17.47% from the company's previous close.</p>
<div class="lb-trans"><p>Zimmer Biomet（紐約證券交易所代碼：ZBH - 獲取免費報告）在週五發佈的報告中，分析師 Stifel Nicolaus 將其目標價格從 115.00 美元上調至 118.00 美元，Benzinga 報道。該公司目前對這家醫療設備提供商的股票給予 “買入” 評級。Stifel Nicolaus 的目標價格意味着該公司股價有 17.47% 的潛在上漲空間。</p>
</div><ul>
<li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>Intuitive Surgical 在機器人手術創新中領先</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on the company. Raymond James Financial boosted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, August 8th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research note on Thursday. Rothschild Redb raised Zimmer Biomet to a &#34;strong-buy&#34; rating in a research report on Thursday. Finally, Rothschild &amp; Co Redburn initiated coverage on Zimmer Biomet in a research report on Thursday. They issued a &#34;buy&#34; rating and a $130.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $113.16.</p>
<div class="lb-trans"><p>其他一些研究分析師最近也對該公司發佈了報告。Raymond James Financial 將 Zimmer Biomet 的目標價格從 104.00 美元上調至 113.00 美元，並在 8 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。加拿大皇家銀行將 Zimmer Biomet 的目標價格從 112.00 美元上調至 115.00 美元，並在 8 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。Redburn Partners 在週四設定了 Zimmer Biomet 的目標價格為 130.00 美元。Rothschild Redb 在週四的研究報告中將 Zimmer Biomet 的評級提升至 “強力買入”。最後，Rothschild &amp; Co Redburn 在週四的研究報告中開始覆蓋 Zimmer Biomet，給予 “買入” 評級和 130.00 美元的目標價格。一位投資分析師對該股票給予 “強力買入” 評級，十位分析師給予 “買入” 評級，七位分析師給予 “持有” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 113.16 美元。</p>
</div><p>Get <strong>Zimmer Biomet</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Zimmer Biomet</strong> 警報：</p>
</div><p><strong>Read Our Latest Research Report on Zimmer Biomet</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Zimmer Biomet 的最新研究報告</strong></p>
</div><h2>Zimmer Biomet Trading Up 0.2%</h2>
<div class="lb-trans"><h2>Zimmer Biomet 股價上漲 0.2%</h2>
</div><ul>
<li>2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家機器人手術公司挑戰 Intuitive Surgical 的領先地位</li>
</ul>
</div><p>ZBH traded up $0.24 during midday trading on Friday, hitting $100.45. 288,498 shares of the company were exchanged, compared to its average volume of 1,964,456. The firm has a market capitalization of $19.90 billion, a P/E ratio of 24.44, a P/E/G ratio of 2.30 and a beta of 0.68. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $114.72. The firm's 50 day moving average price is $99.93 and its 200-day moving average price is $99.46. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.</p>
<div class="lb-trans"><p>週五午盤交易中，ZBH 股價上漲 0.24 美元，達到 100.45 美元。該公司交易了 288,498 股，較其平均交易量 1,964,456 股有所減少。該公司的市值為 199 億美元，市盈率為 24.44，市盈率/增長比率為 2.30，貝塔值為 0.68。Zimmer Biomet 的 1 年最低價為 89.22 美元，1 年最高價為 114.72 美元。該公司的 50 日移動平均價格為 99.93 美元，200 日移動平均價格為 99.46 美元。該公司的速動比率為 0.96，流動比率為 1.87，債務與股本比率為 0.54。</p>
</div><p>Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Zimmer Biomet（紐約證券交易所代碼：ZBH - 獲取免費報告）最後一次公佈財報是在 8 月 7 日，醫療設備提供商報告該季度每股收益為 2.07 美元，超出市場共識預期的 1.98 美元，超出 0.09 美元。該公司該季度的收入為 20.8 億美元，而市場共識預期為 20.6 億美元。Zimmer Biomet 的股本回報率為 12.76%，淨利潤率為 10.51%。該公司的季度收入較去年同期增長了 7.0%。在去年同期，該公司每股收益為 2.01 美元。Zimmer Biomet 已將其 2025 財年的指導目標設定為每股收益 8.100-8.300 美元。整體來看，股票分析師預測 Zimmer Biomet 在當前財年將發佈每股收益 8.22 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><ul>
<li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li>
</ul>
<div class="lb-trans"><ul>
<li>波士頓科學：為什麼這家醫療科技巨頭不會放慢腳步</li>
</ul>
</div><p>In other news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，SVP Lori Winkler 在 9 月 8 日的交易中出售了 1,500 股該公司的股票。股票以 104.15 美元的平均價格出售，總價值為 156,225.00 美元。交易完成後，這位高級副總裁直接持有該公司 6,833 股股票，價值 711,656.95 美元。這代表其持股比例減少了 18.00%。該交易已在與 SEC 的法律文件中披露，文件可通過此鏈接獲取。當前 1.39% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Zimmer Biomet</h2>
<div class="lb-trans"><h2>對 Zimmer Biomet 的對沖基金看法</h2>
</div><p>Several institutional investors have recently modified their holdings of ZBH. Garde Capital Inc. bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $29,000. Menard Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $30,000. Washington Trust Advisors Inc. purchased a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC purchased a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. 88.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者最近修改了對 ZBH 的持股。Garde Capital Inc.在第一季度購買了價值約 29,000 美元的 Zimmer Biomet 新股份。Menard Financial Group LLC 在第四季度購買了價值約 30,000 美元的 Zimmer Biomet 新股份。Washington Trust Advisors Inc.在第一季度購買了價值約 30,000 美元的 Zimmer Biomet 新股份。Columbia River Financial Group LLC 在第一季度購買了價值約 30,000 美元的 Zimmer Biomet 新股份。最後，Cary Street Partners Investment Advisory LLC 在第二季度將其在 Zimmer Biomet 的股份提高了 83.7%。Cary Street Partners Investment Advisory LLC 現在擁有 327 股該醫療設備提供商的股票，價值 30,000 美元，此前在上個季度又購買了 149 股。88.89% 的股票由機構投資者持有。</p>
</div><h2>About Zimmer Biomet</h2>
<div class="lb-trans"><h2>關於 Zimmer Biomet</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.</p>
<div class="lb-trans"><p>Zimmer Biomet Holdings, Inc 及其子公司在全球範圍內運營，作為一家醫療技術公司。該公司設計、製造和銷售骨科重建產品，如膝關節和髖關節產品；S.E.T.產品，包括運動醫學、生物製劑、足踝、四肢和創傷產品；顱面和胸部產品，包括面部和顱骨重建產品，以及固定和穩定胸部骨骼的產品，以促進心臟手術、創傷或胸部畸形後的癒合或重建。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Zimmer Biomet</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>3 Reasons Amazon Could Be at an All-Time High by October</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Workday Rising… To Fresh Record High Stock Prices</li>
<li>Short Selling - The Pros and Cons</li>
<li>McDonald’s: New All-Time Highs Are Inevitable</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Zimmer Biomet</li>
<li>異常交易量的股票：如何實時找到異常交易量股票</li>
<li>亞馬遜可能在十月達到歷史新高的三個原因</li>
<li>價值投資：在 2022 年這是一個好策略嗎？提示：永遠</li>
<li>Workday 上漲……達到新的歷史高股價</li>
<li>賣空 - 利弊分析</li>
<li>麥當勞：新的歷史高點是不可避免的</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=ZBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Zimmer Biomet Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Zimmer Biomet 嗎？</h2>
</div><p>Before you consider Zimmer Biomet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Zimmer Biomet 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Zimmer Biomet 並不在名單上。</p>
</div><p>While Zimmer Biomet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Zimmer Biomet 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Zimmer Biomet（紐約證券交易所代碼：ZBH）被 Stifel Nicolaus 設定了新的目標價為 118.00 美元